Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (EWTX) is a clinical-stage biopharmaceutical company pioneering orally administered therapies for severe musculoskeletal disorders. This page serves as the definitive source for verified corporate announcements, clinical development updates, and strategic business developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated news collection provides essential insights into the company's work on dystrophinopathy treatments like Sevasemten and EDG-7500.
Key categories include quarterly financial results, research collaborations, FDA communications, and scientific conference presentations. All content is rigorously verified to ensure accuracy and relevance for investment research purposes.
Bookmark this page for streamlined access to Edgewise Therapeutics' latest developments in neuromuscular treatment innovation. Check regularly for real-time updates on this clinical-stage biopharma leader's progress.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) reported financial results for Q1 2024, highlighting progress in their skeletal and cardiac muscle programs. Positive two-year results for sevasemten in Becker, advancements in GRAND CANYON pivotal cohort, initiation of CIRRUS-HCM trial, and expansion of LYNX trial in Duchenne were key highlights. The Company also reported cash, cash equivalents, and marketable securities of approximately $532.8 million as of March 31, 2024.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) has appointed Arlene Morris, a seasoned biotechnology industry veteran, to its Board of Directors. With over 30 years of experience in executive management and board roles, Morris brings invaluable expertise in strategic development and operational excellence to the company. As the CEO of Willow Advisors, she advises biotech companies on financing, strategy, and business development. Her previous roles include leading public biotechnology companies like Syndax Pharmaceuticals and Affymax. Edgewise Therapeutics looks forward to leveraging Morris' wealth of experience to advance its mission of helping patients and families affected by serious muscle diseases.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) has dosed the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500, a novel oral cardiac sarcomere modulator designed to address issues associated with obstructive Hypertrophic Cardiomyopathy (HCM). The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with obstructive HCM. Positive preclinical data has led to the advancement of EDG-7500 into this trial, showing encouraging effects on left ventricular outflow tract gradient relief and ventricular function. The company expects to report data from the trial in the third quarter of 2024 and plans to initiate further trials in the second half of 2024 and fourth quarter of 2024.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
